Abstract
Influenza is a cause of significant morbidity and mortality in young children. It is associated with high annual attack rates as well as being responsible for frequent outpatient visits and hospitalisations. Children aged <2 years are at the highest risk for serious illness or death during the influenza season. The neuraminidase inhibitor oseltamivir has been proven to reduce the duration and severity of illness when treatment is commenced within 48 hours of symptom onset. The H1N1 pandemic of 2009 prompted temporary emergency authorisation of oseltamivir use in infants aged <1 year in the USA. In December 2012, Food and Drug Administration (FDA) reinstated approval of oseltamivir to treat children younger than 1 year old including neonates who have shown symptoms of influenza for less than 48 hours. Current data on the use of oseltamivir in neonates and infants are limited. In this review, we evaluated accumulated data on oseltamivir use in newborns, infants and young children with a special focus on pharmacokinetics, efficacy and safety.
Keywords: Children, infants, neonates, oseltamivir, pharmacokinetics, safety.
Infectious Disorders - Drug Targets
Title:Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology
Volume: 13 Issue: 1
Author(s): Eda Karadag-Oncel and Mehmet Ceyhan
Affiliation:
Keywords: Children, infants, neonates, oseltamivir, pharmacokinetics, safety.
Abstract: Influenza is a cause of significant morbidity and mortality in young children. It is associated with high annual attack rates as well as being responsible for frequent outpatient visits and hospitalisations. Children aged <2 years are at the highest risk for serious illness or death during the influenza season. The neuraminidase inhibitor oseltamivir has been proven to reduce the duration and severity of illness when treatment is commenced within 48 hours of symptom onset. The H1N1 pandemic of 2009 prompted temporary emergency authorisation of oseltamivir use in infants aged <1 year in the USA. In December 2012, Food and Drug Administration (FDA) reinstated approval of oseltamivir to treat children younger than 1 year old including neonates who have shown symptoms of influenza for less than 48 hours. Current data on the use of oseltamivir in neonates and infants are limited. In this review, we evaluated accumulated data on oseltamivir use in newborns, infants and young children with a special focus on pharmacokinetics, efficacy and safety.
Export Options
About this article
Cite this article as:
Karadag-Oncel Eda and Ceyhan Mehmet, Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990004
DOI https://dx.doi.org/10.2174/18715265112129990004 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) Genome Diversity of Emerging Paramyxoviruses
Current Genomics Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Antimicrobial Susceptibilities and Treatment Options for Pediatric Mycoplasma pneumoniae Infections - Does Macrolide Resistance Matter?
Current Pediatric Reviews Novel Synthetic Compounds as Potential Anticryptococcal Agents
Current Organic Synthesis Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective
Current Analytical Chemistry Anti-influenza Virus Effects of Catechins: A Molecular and Clinical Review
Current Medicinal Chemistry A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates
Current Gene Therapy Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Safe and Effective Delivery of Amphotericin B: A Survey of Patents
Recent Patents on Nanotechnology Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine